The increasing availability of techniques [i.e., mini-mental state examination (MMSE), cerebrospinal fluid (CSF) biomarker analysis, positron emission tomography (PET) with β -amyloid or tau tracers, brain magnetic resonance imaging (MRI)] able to detect in vivo AD pathological hallmarks (Santangelo et al., 2020;Arevalo-Rodriguez et al., 2021). The gene discussed is MAPT; the disease is Alzheimer disease.